About the company
Krystal Biotech Inc, a leading healthcare company based in the United States, is making remarkable strides in the field of gene therapy. The company is passionately driven by the mission to enhance the quality of life for patients suffering from debilitating diseases. By harnessing the power of its revolutionary gene therapy platform known as STAR-D, Krystal Biotech is pioneering novel treatments for rare or orphan dermatological conditions caused by the absence or mutation of a single gene. Gene therapy holds immense potential in the field of medicine. It involves introducing genetic material into a patient's cells to correct a faulty gene or provide a missing gene. What sets Krystal Biotech apart is its dedication to developing user-friendly, redosable gene therapies. These therapies empower patients to take control of their own treatment conveniently and effectively. The cornerstone of Krystal Biotech's success lies in its proprietary gene therapy platform, STAR-D. This advanced platform, which stands for Skin TARgeted Delivery, enables the efficient delivery of therapeutic genes directly into the skin cells. By utilizing viral vectors, namely modified herpes simplex viruses, STAR-D ensures the precise targeting of the affected cells while limiting off-target effects. Currently, Krystal Biotech is focusing on addressing rare or orphan dermatological indications, which often lack effective treatment options. Such conditions, often caused by genetic mutations, have a profound impact on patients' lives, leading to severe physical and psychological distress. By leveraging the capabilities of STAR-D, Krystal Biotech has successfully developed gene therapies for these underserved patient populations. The company's ultimate goal is to expand its pipeline to include a broader range of dermatological indications. With their expertise in gene therapy and the versatility of the STAR-D platform, Krystal Biotech aims to revolutionize the treatment landscape for numerous skin-related diseases. By doing so, it aspires to improve the lives of millions of patients worldwide. Krystal Biotech's commitment to innovation and patient well-being is evident in their tireless research and development efforts. The company actively collaborates with leading experts in dermatology and genetics to uncover new therapeutic targets and optimize their gene therapy treatments. By combining cutting-edge science with compassionate patient care, Krystal Biotech strives to make a meaningful difference in the lives of those affected by debilitating skin conditions. In addition to its scientific advancements, Krystal Biotech places a strong emphasis on safety and regulatory compliance. The company adheres to rigorous quality control measures to ensure that its gene therapies meet the highest standards of safety and efficacy. By maintaining a robust safety profile, Krystal Biotech instills confidence in both patients and regulatory bodies, paving the way for broader acceptance and adoption of gene therapy treatments. Krystal Biotech's accomplishments and potential have not gone unnoticed within the healthcare industry. The company has received numerous accolades and grants for its groundbreaking work, further validating its position as a leader in the field of dermatological gene therapy. With a dedicated team of professionals and a vision for a healthier future, Krystal Biotech continues to push boundaries and unlock the transformative power of gene therapy. In conclusion, Krystal Biotech is revolutionizing the healthcare landscape with its easy to use, redosable gene therapies. Utilizing its proprietary gene therapy platform, STAR-D, the company is addressing rare or orphan dermatological indications caused by genetic mutations. With a steadfast commitment to innovation and patient well-being, Krystal Biotech is poised to expand its portfolio and make a lasting impact on the lives of patients worldwide.
Website: https://www.krystalbio.com
Data updated: June 2, 2026
